Drugs Made In America Acquisition II Corp. Unit
Drugs Made In America Acquisition II Corp. Unit (DMIIU) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0002040475 · DMIIU · NASDAQ · as of Jun 8, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0002040475 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Drugs Made In America Acquisition II Corp. Unit (NASDAQ: DMIIU) has submitted 44 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Financial Services sector company with CIK 0002040475, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Drugs Made In America Acquisition II Corp. Unit's most comprehensive regulatory disclosure. The most recent Drugs Made In America Acquisition II Corp. Unit 10-K was filed on 2026-04-15 for fiscal year ending 2026. Historical DMIIU 10-K annual reports are available from 2025 through 2026.
Investors researching Drugs Made In America Acquisition II Corp. Unit SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
DMIIU SEC Filings · 8 questionsDrugs Made In America Acquisition II Corp. Unit (DMIIU) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 44 filings and access original documents at no cost. Drugs Made In America Acquisition II Corp. Unit's CIK is 0002040475.